Cyclophilin inhibitors for hepatitis C therapy

Clin Liver Dis. 2013 Feb;17(1):129-39. doi: 10.1016/j.cld.2012.09.008.

Abstract

This article highlights a unique time in the history of hepatitis C therapy. In the last few years new families of direct-acting antivirals have emerged, that block different viral proteins to interrupt viral replication, such as protease, NS5A inhibitors, and NS5B inhibitors. There are few host-targeted agents in development; currently cyclophilin inhibitors are the only host-targeted agents in advanced development. One of these new agents has now progressed to phase 3 clinical trials; in this review article their potential role as a future therapy to cure hepatitis C is discussed.

Publication types

  • Review

MeSH terms

  • Antiviral Agents / therapeutic use
  • Cyclophilins / antagonists & inhibitors*
  • Cyclosporine / therapeutic use
  • Cyclosporins / therapeutic use
  • Drug Therapy, Combination
  • Enzyme Inhibitors / therapeutic use*
  • Hepacivirus / enzymology*
  • Hepacivirus / genetics
  • Hepatitis C / drug therapy*
  • Humans
  • Interferon-alpha / therapeutic use
  • Polyethylene Glycols / therapeutic use
  • Recombinant Proteins / therapeutic use
  • Ribavirin / therapeutic use
  • Viral Nonstructural Proteins / antagonists & inhibitors

Substances

  • Antiviral Agents
  • Cyclosporins
  • Enzyme Inhibitors
  • Interferon-alpha
  • Recombinant Proteins
  • Viral Nonstructural Proteins
  • Polyethylene Glycols
  • Ribavirin
  • Cyclosporine
  • (melle-4)cyclosporin
  • NS-5 protein, hepatitis C virus
  • Cyclophilins
  • peginterferon alfa-2a
  • alisporivir
  • SCY-635